ResApp Health Limited (ASX: RAP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
ResApp Health Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ResApp Health Limited (ASX: RAP)
Latest News
52-Week Highs
Why the ResApp share price rocketed 17% higher to a 52-week high today
Share Gainers
Why Nufarm, Paradigm, ResApp, & Zip Co shares charged higher today
Share Gainers
ResApp share price surges 11% higher on positive update
Share Gainers
Why the ResApp share price rocketed 30% higher today
Share Market News
Top brokers name 3 ASX shares to buy
Share Gainers
Why Appen, Bubs, EML Payments, & ResApp shares stormed higher today
Share Gainers
Why the ResApp Health share price rocketed 36% higher today
Share Market News
2 egregious investing mistakes to avoid
Share Fallers
Why the Admedus share price is sinking again on more big losses
Share Market News
Leading brokers name 3 ASX shares to buy today
Share Gainers
Why BWX, Kogan, OceanaGold, and ResApp shares are storming higher
Share Market News
Are Mesoblast shares ready to shoot higher?
RAP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Roger Aston | Non-Executive ChairmanNon-Executive Director | Jul 2015 |
Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
|
Dr Michael Stein | Non-Executive Director | Apr 2020 |
Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
|
Mr Brian Willoughby Leedman | Executive Director Corporate Affairs | May 2021 |
Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
|
Mr Christopher Ntoumenopoulos | Non-Executive Director | Jan 2015 |
Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
|
Dr Anthony (Tony) Keating | Chief Executive OfficerManaging Director | Jul 2015 |
Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
|
Ms Nicola (Nicki) Maxine Farley | Company Secretary |
-
|
|
Nicola (Nicki) Maxine Farley | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 90,509,172 | 10.53% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> | 46,498,352 | 5.41% |
J P Morgan Nominees Australia Pty Limited | 22,398,291 | 2.61% |
Mr Frank Weng Thong Chew | 18,453,000 | 2.15% |
HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> | 17,974,966 | 2.09% |
BNP Paribas Noms Pty Ltd <DRP> | 14,977,050 | 1.74% |
HSBC Custody Nominees (Australia) Limited GSCO ECA | 12,567,531 | 1.46% |
Mr Yongsheng Peng & Mrs Yuezhen Xie | 11,667,602 | 1.36% |
Mr Anthony James Keating | 10,225,000 | 1.19% |
Citicorp Nominees Pty Limited | 9,962,873 | 1.16% |
Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> | 8,437,500 | 0.98% |
Narhex Life Sciences Developments Pty Ltd | 7,997,005 | 0.93% |
CEM International (Asia) Pty Ltd | 7,849,888 | 0.91% |
Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> | 7,510,228 | 0.87% |
Mr Trent Antony Goodrick | 7,000,000 | 0.81% |
Queensland Forest Industries Pty Ltd | 6,502,500 | 0.76% |
Mishtalem Pty Ltd | 6,500,000 | 0.76% |
Super Dino Pty Ltd <Dino Super A/C> | 5,430,779 | 0.63% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 5,378,484 | 0.63% |
Paranji Super Fund Pty Ltd <Paranji Superfund A/C> | 5,285,000 | 0.61% |